Study #2021-1033
An open-label, multi-center, non-randomized phase I dose escalation study to investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 given as monotherapy in patients with relapsed or refractory T-cell Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
ONO-4685
Description
This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed or Refractory T Cell Lymphoma
Study phase:
Phase I
Physician name:
Swaminathan Iyer
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.